Therapeutic Gene Editing of APOE4 in Sporadic Alzheimer's Disease via Prime Editor 7
Advanced Science · 2026
DOI: 10.1002/advs.76658 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Yunkyung Kim und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Stem Cells and Regenerative Medicine (ISR), Department of Chemistry, Dongguk University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Alzheimer Disease, Apolipoprotein E4, Gene Editing. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Republic of Korea, Korea Health Industry Development Institute (KHIDI), Ministry of Science and ICT and Ministry of Health and Welfare, Republic of Korea.
Themen: Demenz
Abstract (Originalsprache)
The apolipoprotein E4 (APOE4) allele is the strongest genetic risk factor for sporadic Alzheimer's disease (AD), driving Aβ accumulation, tau pathology, and synaptic dysfunction. Allele‐specific correction of APOE4 represents a promising therapeutic strategy to mitigate disease progression. In this study, we developed an APOE4‐specific prime editing strategy based on an optimized APOE4‐targeting pegRNA, enabling precise and efficient conversion of the APOE4 allele to the lower‐risk APOE3 variant. We found that PE7 targeting the APOE4 allele achieved robust and specific editing without detectable off‐target effects. This correction reduced ApoE4 protein levels and attenuated key AD‐related pathologies, including Aβ42 accumulation, tau phosphorylation, and activation of the ERK1/2 pathway in APP/APOE4 knock‐in (KI) mice. Notably, PE7 treatment enhanced neuronal survival and improved cognitive performance in these mice. Furthermore, in human induced neurons derived from APOE3/4 heterozygous AD patient fibroblasts, PE7 consistently corrected the APOE4 allele and suppressed both amyloid‐ and tau‐associated pathologies. These findings establish PE7‐mediated APOE4 correction as a precise and efficient therapeutic genome‐editing strategy with translational potential for sporadic AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Stem Cells and Regenerative Medicine (ISR), Department of Chemistry, Dongguk University, Seoul, Republic of Korea.
- Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of Korea.
- College of Pharmacy & Medical Research Center, Chungbuk National University, Cheongju, Republic of Korea.
- School of Biomedical Health Science and Engineering, University of Ulsan, Ulsan, Republic of Korea.
ORCID-Profile: Hanseul Park, Jongpil Kim
Förderung
- Ministry of Education, Republic of Korea
- Korea Health Industry Development Institute (KHIDI)
- Ministry of Science and ICT and Ministry of Health and Welfare, Republic of Korea
Zitieren
APA
Kim, Y., Lee, G., An, S., Park, H., Kim, H., Kim, J., Kang, S., Kim, S., Kwon, D., Park, J., Hwang, Y., Kim, S., Yuan, X., Jeong, J., Lee, H., Kim, H. K., & Kim, J. (2026). Therapeutic Gene Editing of APOE4 in Sporadic Alzheimer's Disease via Prime Editor 7. Advanced Science. https://doi.org/10.1002/advs.76658
Vancouver
Kim Y, Lee G, An S, Park H, Kim H, Kim J, et al. Therapeutic Gene Editing of APOE4 in Sporadic Alzheimer's Disease via Prime Editor 7. Advanced Science. 2026. doi:10.1002/advs.76658
BibTeX
@article{Kim2026,
author = {Kim, Yunkyung and Lee, Gaeun and An, Saemin and Park, Hanseul and Kim, Hongwon and Kim, Jisung and Kang, Soi and Kim, Sumin and Kwon, Daeyeol and Park, Jeonghyun and Hwang, Yerim and Kim, Seonghun and Yuan, Xiuwen and Jeong, Jaehoon and Lee, Hamin and Kim, Hui Kwon and Kim, Jongpil},
title = {Therapeutic Gene Editing of APOE4 in Sporadic Alzheimer's Disease via Prime Editor 7},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76658}
}
EUVIMED